Correlation Between Bristol Myers and Entrada Therapeutics

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Entrada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Entrada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Entrada Therapeutics, you can compare the effects of market volatilities on Bristol Myers and Entrada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Entrada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Entrada Therapeutics.

Diversification Opportunities for Bristol Myers and Entrada Therapeutics

0.12

Correlation Coefficient

Bristol Myers  Entrada Therapeutics

Average diversification

The 3 months correlation between Bristol and Entrada is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Entrada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entrada Therapeutics and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Entrada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entrada Therapeutics has no effect on the direction of Bristol Myers i.e., Bristol Myers and Entrada Therapeutics go up and down completely randomly.

Pair Corralation between Bristol Myers and Entrada Therapeutics

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.62 times more return on investment than Entrada Therapeutics. However, Bristol Myers Squibb is 1.61 times less risky than Entrada Therapeutics. It trades about -0.06 of its potential returns per unit of risk. Entrada Therapeutics is currently generating about -0.11 per unit of risk. If you would invest  5,876  in Bristol Myers Squibb on November 29, 2024 and sell it today you would lose (138.00) from holding Bristol Myers Squibb or give up 2.35% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	95.45%
Values	Daily Returns

Bristol Myers Squibb  vs.  Entrada Therapeutics

Bristol Myers Squibb

Risk-Adjusted Performance

Very Weak

Over the last 90 days Bristol Myers Squibb has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, Bristol Myers is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Entrada Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Entrada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Bristol Myers and Entrada Therapeutics

The main advantage of trading using opposite Bristol Myers and Entrada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Entrada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entrada Therapeutics will offset losses from the drop in Entrada Therapeutics' long position.

The idea behind Bristol Myers Squibb and Entrada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.